Sökning: "Factor IX"
Visar resultat 1 - 5 av 31 avhandlingar innehållade orden Factor IX.
Sammanfattning : The aim of the thesis was to increase cost-effectiveness in prophylactic treatment of haemophilia. Prophylaxis is effective to prevent bleedings and arthropathy, but the high cost limits its use. First, a new distribution system for clotting factor concentrates was implemented in Sweden to improve availability and reduce risks and costs. LÄS MER
Sammanfattning : Introduction: Haemophilia A (HA) and B (HB) are two of our most common inherited bleeding disorders and are due to a variety of gene mutations. Aims: The overall objective of the present research was to perform clinical and basic scientific studies on haemophilia in Sweden to further improve and individualise the care of haemophilia patients and their relatives. LÄS MER
3. HEMOPHILIA A AND B WITH SPECIAL REFERENCE TO INHIBITOR DEVELOPMENT AND EXPERIMENTAL STUDIES OF FACTORS VIII AND IX
Sammanfattning : The general objective of the research underlying this dissertation was to conduct clinical and basic scientific studies to further elucidate the hemophilia and the coagulation process, with the goal of improving the care of families with these disorders. More specific aims were to evaluate epidemiological, genetic, clinical, and biochemical aspects of the development of inhibitors (antibodies) against FVIII and FIX in Swedish patients with hemophilia A and B (papers I, II, and III). LÄS MER
Sammanfattning : Haemophilia is a recessive genetic bleeding disorder in which coagulation time is prolonged due to the absence or malfunction of either of the serum proteins Factor VIII or IX. Joint destruction following repeated haemarthroses is the main cause of morbidity in haemophiliacs, and such arthropathy can be prevented or postponed by implementing prophylactic therapy with factor concentrate at an early age. LÄS MER
Sammanfattning : The homologous blood coagulation factors V (FV) and factor VIII (FVIII) are important at sites of vascular injury for the amplification of the clotting cascade. Activated FV (FVa) serves as a cofactor to the enzyme activated factor X (FXa) in the activation of prothrombin. This complex is called the prothrombinase complex. LÄS MER